Co‐delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy

&NA; Heterogeneous distribution of drug inside tumor is ubiquitous, causing regional insufficient chemotherapy, which might be the hotbed for drug resistance, tumor cell repopulation and metastasis. Herein, we verify, for the first time, that heterogeneous drug distribution induced insufficient chemotherapy would accelerate the process of epithelial mesenchymal transition (EMT), consequently resulting in the promotion of tumor metastasis. To eliminate the insufficient chemotherapy promoted metastasis, we conceived a co‐delivery strategy by hydroxyethyl starch‐polylactide (HES‐PLA) nanoparticle, in which DOX and TGF‐&bgr; receptor inhibitor, LY2157299 (LY), were administered together. In vitro and in vivo studies demonstrate that this co‐delivery strategy can simultaneously suppress primary tumor and distant metastasis. Further study on immunofluorescence images of primary tumor verifies that low dose of DOX exasperates the EMT process, whereas the co‐delivery nanoparticle can dramatically inhibit the progression of EMT. We reveal the impact of heterogeneous drug distribution on tumor metastasis and develop an effective co‐delivery strategy to suppress the metastasis, providing guidance for clinical cancer therapy. Graphical abstract Heterogeneous drug distribution inside tumor induces regional insufficient chemotherapy, which accelerates EMT process, consequently promoting tumor metastasis. Co‐delivery nanoparticle can suppress EMT process via blocking TGF‐&bgr; pathway, inhibiting tumor metastasis. Figure. No Caption available.

[1]  H. Moses,et al.  Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. , 2007, The Journal of clinical investigation.

[2]  Wen-juan Wang,et al.  Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells , 2009, Clinical Cancer Research.

[3]  Bixiang Zhang,et al.  Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. , 2009, Cancer letters.

[4]  J. Boratýnski,et al.  Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy , 2014, Pharmacology research & perspectives.

[5]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[6]  Huibi Xu,et al.  Redox-Sensitive Hydroxyethyl Starch-Doxorubicin Conjugate for Tumor Targeted Drug Delivery. , 2016, ACS applied materials & interfaces.

[7]  J. Gray,et al.  Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. , 1998, Journal of immunology.

[8]  Honggang Yu,et al.  Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells , 2015, Molecular medicine reports.

[9]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.

[10]  M. Untch,et al.  The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Li Chen,et al.  Drug binding rate regulates the properties of polysaccharide prodrugs. , 2016, Journal of materials chemistry. B.

[12]  Aniruddha Roy,et al.  Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Shuning He,et al.  Transforming growth factor-β signalling controls human breast cancer metastasis in a zebrafish xenograft model , 2013, Breast Cancer Research.

[14]  Jianbin Tang,et al.  The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment. , 2015, ACS nano.

[15]  Luzhe Sun,et al.  Doxorubicin in Combination with a Small TGFβ Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models , 2010, PloS one.

[16]  F. Danhier,et al.  To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[17]  James Chen Yong Kah,et al.  Exploiting the protein corona around gold nanorods for loading and triggered release. , 2012, ACS nano.

[18]  Z. Sideratou,et al.  Drug Delivery Systems Based on Hydroxyethyl Starch. , 2017, Bioconjugate chemistry.

[19]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[20]  Kazunori Kataoka,et al.  Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling , 2007, Proceedings of the National Academy of Sciences.

[21]  R. Bernards,et al.  TGF-β: An emerging player in drug resistance , 2013, Cell cycle.

[22]  J. Balko,et al.  TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. , 2013, The Journal of clinical investigation.

[23]  Huibi Xu,et al.  α-Amylase- and Redox-Responsive Nanoparticles for Tumor-Targeted Drug Delivery. , 2017, ACS applied materials & interfaces.

[24]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[25]  R. Holmdahl,et al.  The molecular pathogenesis of collagen-induced arthritis in mice—a model for rheumatoid arthritis , 2002, Ageing Research Reviews.

[26]  M. Sporn,et al.  Transforming Growth Factor 81 Positively Regulates Its Own Expression in Normal and Transformed Cells * , 2001 .

[27]  Hideyoshi Harashima,et al.  A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. , 2011, Advanced drug delivery reviews.

[28]  Ling Yu,et al.  Cisplatin promotes mesenchymal-like characteristics in osteosarcoma through Snail , 2016, Oncology letters.

[29]  G. Winter,et al.  The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes. , 2013, Biomaterials.

[30]  M. Anderton,et al.  Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors , 2011, Toxicologic pathology.

[31]  J. Lankelma,et al.  Doxorubicin gradients in human breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  H. Moses,et al.  The roles of TGFβ in the tumour microenvironment , 2013, Nature Reviews Cancer.

[33]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[34]  I. Tannock,et al.  Repopulation of cancer cells during therapy: an important cause of treatment failure , 2005, Nature Reviews Cancer.

[35]  Ian F Tannock,et al.  Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[37]  G. Giannelli,et al.  Blocking transforming growth factor–beta up‐regulates E‐cadherin and reduces migration and invasion of hepatocellular carcinoma cells , 2008, Hepatology.

[38]  P. Gascard,et al.  Coordinate transcriptional and translational repression of p53 by TGF-β1 impairs the stress response. , 2013, Molecular cell.

[39]  C. Kang,et al.  AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis. , 2015, Cancer letters.

[40]  R. Strauss,et al.  An international view of hydroxyethyl starches , 1999, Intensive Care Medicine.

[41]  Iñaki F Trocóniz,et al.  Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. , 2008, European journal of cancer.

[42]  Yong-jig Cho,et al.  Antimetastatic role of Smad4 signaling in colorectal cancer. , 2010, Gastroenterology.

[43]  R. Jain,et al.  Strategies for advancing cancer nanomedicine. , 2013, Nature materials.

[44]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[45]  Youqing Shen,et al.  Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization , 2017, Advanced materials.

[46]  D. Zheng,et al.  Targeting epithelial-mesenchymal transition: Metal organic network nano-complexes for preventing tumor metastasis. , 2017, Biomaterials.

[47]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[48]  S. L. Gonias,et al.  High-resolution imaging of the dynamic tumor cell–vascular interface in transparent zebrafish , 2007, Proceedings of the National Academy of Sciences.

[49]  Jean Paul Thiery,et al.  EMT: 2016 , 2016, Cell.

[50]  Huan Meng,et al.  Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. , 2013, ACS nano.

[51]  Ying Wan,et al.  Enhancing Doxorubicin Delivery toward Tumor by Hydroxyethyl Starch-g-Polylactide Partner Nanocarriers. , 2017, ACS applied materials & interfaces.

[52]  G. Winter,et al.  Controlled shielding and deshielding of gene delivery polyplexes using hydroxyethyl starch (HES) and alpha-amylase. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[53]  Xuesi Chen,et al.  Targeted hydroxyethyl starch prodrug for inhibiting the growth and metastasis of prostate cancer. , 2017, Biomaterials.

[54]  S. Ran,et al.  Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. , 2014, Cancer research.

[55]  A. Laurence,et al.  Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma , 2014, Hepatology.

[56]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[57]  C. Brinckerhoff,et al.  Consequences of altered TGF-β expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects , 2002, Oncogene.

[58]  Junjian Z. Chen,et al.  Efficient extravasation of tumor-repopulating cells depends on cell deformability , 2016, Scientific Reports.